Overview

• The atlas includes around 60 BTC cell lines, with 30 newly developed models, capturing the genetic and biological diversity of these rare and aggressive cancers.
• Each cell line underwent extensive multi-omic profiling, including whole-genome sequencing, proteomic and transcriptomic analyses, and CRISPR-Cas9 dependency screens.
• Molecular subtypes with distinct genetic alterations, dependencies, and drug response profiles were identified, offering insights into tailored therapeutic strategies.
• The dataset has been integrated into DepMap, a global open-access resource, to foster collaboration and advance BTC research across the scientific community.
• Next steps include validating subtypes in additional patient cohorts and preclinical testing of promising therapeutic candidates to accelerate clinical translation.